Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions	Apr. 02, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 2,752	$ 4,477
Accounts receivable, less allowances of $170 and $150	7,889	7,977
Inventories	5,483	5,051
Contract assets, net	1,064	968
Other current assets	1,588	1,640
Total current assets	18,776	20,113
Property, plant and equipment, net	8,448	8,333
Acquisition-related intangible assets, net	19,378	20,113
Other assets	4,424	4,640
Goodwill	41,721	41,924
Total assets	92,747	95,123
Current liabilities:
Short-term obligations and current maturities of long-term obligations	1,866	2,537
Accounts payable	2,667	2,867
Accrued payroll and employee benefits	1,634	2,427
Contract liabilities	2,871	2,655
Other accrued expenses	3,032	2,950
Total current liabilities	12,070	13,436
Deferred income taxes	3,493	3,837
Other long-term liabilities	4,664	4,540
Long-term obligations	31,389	32,333
Redeemable noncontrolling interest	113	122
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 439,530,820 and 439,154,741 shares issued	440	439
Capital in excess of par value	16,292	16,174
Retained earnings	37,528	35,431
Treasury stock at cost, 48,068,820 and 44,720,112 shares	(10,961)	(8,922)
Accumulated other comprehensive items	(2,343)	(2,329)
Total Thermo Fisher Scientific Inc. shareholders’ equity	40,956	40,793
Noncontrolling interests	62	62
Total equity	41,018	40,855
Total liabilities, redeemable noncontrolling interest and equity	$ 92,747	$ 95,123